Role of CDK4/6 Inhibitors in HR+/HER2- EBC

CE / CME

Risk Factors for Recurrence, Molecular Testing, and Treatment of Patients With HR-Positive/HER2-Negative EBC

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: January 24, 2025

Expiration: January 23, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is associated with high risk of recurrence and would help to inform optimal adjuvant therapy for newly diagnosed patients with HR-positive/HER2-negative EBC?

2.

A 57-year-old postmenopausal woman presents with a palpable mass in her right breast. Mammogram/ultrasound showed a >5 cm mass with enlarged, suspicious ALN. Core biopsy reveals grade 1 invasive lobular carcinoma, ER-positive/PR-positive/HER2-negative disease, and lymph node biopsy showed node-positive carcinoma. CT staging and germline testing are negative. The patient has preexisting QT prolongation.


Right breast mastectomy and ALN dissection were performed and reveal 5.2 cm mass, grade 1 invasive lobular carcinoma with 2/3 positive lymph nodes. She received adjuvant chemotherapy with dose-dense doxorubicin plus cyclophosphamide followed by 12 weeks of paclitaxel. She undergoes radiotherapy to the right chest wall and regional nodes.

Based on the patient’s tumor characteristics, predictive biomarkers and existing comorbidities, which of the following would you recommend as the most appropriate systemic adjuvant therapy for this patient?